Cargando…
Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study
PURPOSE: Programmed cell death 1 (PD-1) inhibitors are ineffective as monotherapy for the treatment of soft tissue sarcomas (STS). However, increasing evidence shows that the combination of PD-1 inhibitors and chemotherapy is efficacious and safe for many types of malignancies, including STS. This s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047982/ https://www.ncbi.nlm.nih.gov/pubmed/32158266 http://dx.doi.org/10.2147/CMAR.S237300 |
_version_ | 1783502216689090560 |
---|---|
author | Tian, Zhichao Yang, Yonghao Yang, Jinpo Zhang, Peng Zhang, Fan Du, Xinhui Li, Chao Wang, Jiaqiang |
author_facet | Tian, Zhichao Yang, Yonghao Yang, Jinpo Zhang, Peng Zhang, Fan Du, Xinhui Li, Chao Wang, Jiaqiang |
author_sort | Tian, Zhichao |
collection | PubMed |
description | PURPOSE: Programmed cell death 1 (PD-1) inhibitors are ineffective as monotherapy for the treatment of soft tissue sarcomas (STS). However, increasing evidence shows that the combination of PD-1 inhibitors and chemotherapy is efficacious and safe for many types of malignancies, including STS. This study aimed to assess the safety and efficacy of doxorubicin chemotherapy plus PD-1 inhibitor in the treatment of metastatic STS. PATIENTS AND METHODS: We retrospectively reviewed 21 patients with metastatic STS who received doxorubicin chemotherapy plus a PD-1 inhibitor between November 2017 and October 2018. RESULTS: The objective response rate was 47.6%, the disease control rate was 71.40%, and the median progression-free survival was 6 months (95% CI, 2–8 months). The average change in target lesion diameter from baseline was −25.15 ± 41.61. Majority of the patients experienced grade 1/2 adverse events (AEs), the grade 3/4 AEs were few. The most common grade 3/4 AEs were as follows: leukopenia (23.8%) and anemia (19.0%). Immune-related AEs were common and included hypothyroidism (14.3%) and pneumonitiss (9.5%). No drug related deaths occurred. CONCLUSION: This study provides preliminary evidence that the combination of doxorubicin chemotherapy and PD-1 inhibitor for advanced STS is safe and effective. We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas. |
format | Online Article Text |
id | pubmed-7047982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70479822020-03-10 Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study Tian, Zhichao Yang, Yonghao Yang, Jinpo Zhang, Peng Zhang, Fan Du, Xinhui Li, Chao Wang, Jiaqiang Cancer Manag Res Original Research PURPOSE: Programmed cell death 1 (PD-1) inhibitors are ineffective as monotherapy for the treatment of soft tissue sarcomas (STS). However, increasing evidence shows that the combination of PD-1 inhibitors and chemotherapy is efficacious and safe for many types of malignancies, including STS. This study aimed to assess the safety and efficacy of doxorubicin chemotherapy plus PD-1 inhibitor in the treatment of metastatic STS. PATIENTS AND METHODS: We retrospectively reviewed 21 patients with metastatic STS who received doxorubicin chemotherapy plus a PD-1 inhibitor between November 2017 and October 2018. RESULTS: The objective response rate was 47.6%, the disease control rate was 71.40%, and the median progression-free survival was 6 months (95% CI, 2–8 months). The average change in target lesion diameter from baseline was −25.15 ± 41.61. Majority of the patients experienced grade 1/2 adverse events (AEs), the grade 3/4 AEs were few. The most common grade 3/4 AEs were as follows: leukopenia (23.8%) and anemia (19.0%). Immune-related AEs were common and included hypothyroidism (14.3%) and pneumonitiss (9.5%). No drug related deaths occurred. CONCLUSION: This study provides preliminary evidence that the combination of doxorubicin chemotherapy and PD-1 inhibitor for advanced STS is safe and effective. We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas. Dove 2020-02-24 /pmc/articles/PMC7047982/ /pubmed/32158266 http://dx.doi.org/10.2147/CMAR.S237300 Text en © 2020 Tian et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Tian, Zhichao Yang, Yonghao Yang, Jinpo Zhang, Peng Zhang, Fan Du, Xinhui Li, Chao Wang, Jiaqiang Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study |
title | Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study |
title_full | Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study |
title_fullStr | Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study |
title_full_unstemmed | Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study |
title_short | Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study |
title_sort | safety and efficacy of pd-1 inhibitors plus chemotherapy in advanced soft tissue sarcomas: a retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047982/ https://www.ncbi.nlm.nih.gov/pubmed/32158266 http://dx.doi.org/10.2147/CMAR.S237300 |
work_keys_str_mv | AT tianzhichao safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT yangyonghao safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT yangjinpo safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT zhangpeng safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT zhangfan safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT duxinhui safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT lichao safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy AT wangjiaqiang safetyandefficacyofpd1inhibitorspluschemotherapyinadvancedsofttissuesarcomasaretrospectivestudy |